[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/","commit":"28a6975696","date":"2026-09-10","author":"Jude Gomila","message":"Tone pass: solution and mechanism first; frightening figures behind a click","file":"src/data/cancers.ts","type":"changed","fields":[{"field":"burden","before":"\"About 300,000 CNS tumours occur per year; glioblastoma median survival is about 15 months.\"","after":"\"About 300,000 CNS tumours occur per year, most of them not glioblastoma; IDH-mutant and paediatric low-grade gliomas can be lived with for decades and now have targeted drugs. Median survival for glioblastoma with ma..."},{"field":"tldr","before":"\"Glioblastoma is the most lethal brain tumour, barely improved since 2005. Low-grade IDH-mutant gliomas, by contrast, got their first targeted drug in 2024.\"","after":"\"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M)...."},{"field":"openProblems","before":"[\"Blood-brain barrier.\", \"Immunologically cold, heterogeneous, infiltrative.\", \"No progress in glioblastoma survival in 20 years.\"]","after":"[\"Blood-brain barrier.\", \"Immunologically cold, heterogeneous, infiltrative.\", \"Glioblastoma: no systemic drug has beaten the 2005 standard; getting drugs across the blood-brain barrier is the crux.\"]"}]},{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/cancers.ts","type":"changed","fields":[{"field":"burden","before":"\"~300,000 CNS tumours per year; glioblastoma median survival ~15 months.\"","after":"\"About 300,000 CNS tumours occur per year; glioblastoma median survival is about 15 months.\""},{"field":"tldr","before":"\"The most lethal brain tumour, barely improved since 2005. Low-grade IDH-mutant gliomas, by contrast, got their first targeted drug in 2024.\"","after":"\"Glioblastoma is the most lethal brain tumour, barely improved since 2005. Low-grade IDH-mutant gliomas, by contrast, got their first targeted drug in 2024.\""}]},{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/","commit":"cebb34a709","date":"2026-09-08","author":"Jude Gomila","message":"Guideline mapping on every standard-of-care row; sourced biomarker prevalence for 59 targets; GuidelineChip, PrevalenceTable, CancerPrevalen","file":"src/data/cancers.ts","type":"changed","fields":[{"field":"standardOfCare","before":"[\n      { setting: \"Glioblastoma\", approach: \"Resection → RT + temozolomide → TTFields; lomustine/bevacizumab at relapse.\", refs: [\"fluorescence-guided-surgery\", \"imrt-igrt\", \"optune\"] },\n      { setting: \"IDH-mutant ...","after":"[\n      { setting: \"Glioblastoma\", approach: \"Resection → RT + temozolomide → TTFields; lomustine/bevacizumab at relapse.\", refs: [\"fluorescence-guided-surgery\", \"imrt-igrt\", \"optune\"], guideline: { version: \"NCCN Gui..."}]}]